DeveloGen (www.develogen.com) will transfer rights to its Phase II treatment for diabetes to Andromeda. It will receive developmental and regulatory milestones and royalties upon commercialization. It is expected that Andromeda will continue the ongoing Phase III study for DiaPep277.

Next articleUMMZ Periodical Cicada Page